LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro

  • Shen Gu
  • Jun Chen
  • Qun Zhou
  • Minghao Yan
  • Jian He
  • Xiaodong Han
  • Yudong QiuEmail author
Original Article



The leucine-rich repeat kinase 2 (LRRK2) gene was confirmed to be associated with a variety of diseases, while the physiological function of LRRK2 remains poorly understood. Intrahepatic cholangiocarcinoma (ICC) has over the last 10 years become the focus of increasing concern largely. Despite recent progress in the standard of care and management options for ICC, the prognosis for this devastating cancer remains dismal.


A total of 57 consecutive ICC patients who underwent curative hepatectomy in our institution were included in our study. We conduct a retrospective study to evaluate the prognostic value of LRRK2 in ICC after resection. The mechanism of LRRK2 in ICC development was also investigated in vitro.


All patients were divided into two groups according to the content of LRRK2 in the tissue microarray blocks via immunohistochemistry: low-LRRK2 group (n = 33) and high-LRRK2 group (n = 24). The recurrence-free survival rate of high-LRRK2 group was significantly poorer than that of low-LRRK2 group (P = 0.010). Multivariate analysis showed high-LRRK2 was the prognostic factor for recurrence-free survival after hepatectomy. We demonstrated that downregulation of LRRK2 depressed the proliferation and metastasis of ICC cells in vitro.


We provide evidence that LRRK2 was an independent prognostic factor for ICC in humans by participating in the proliferation and metastasis of ICC cells.


Leucine-rich repeat kinase 2 Intrahepatic cholangiocarcinoma Prognosis Cell proliferation Cell migration 



We thank Hui Zhao, Chuang Chen, Xiaopeng Yan, and Mingxuemei Jiang for assistance. The authors declare they have no competing interests. This work was supported by the National Natural Science Foundation of China (81470866) and the Key Medical Subjects of Jiangsu Province (ZDRCA2016057).

Compliance with Ethical Standards

Conflict of interest

Shen Gu, Jun Chen, Minghao Yan, Qun Zhou, Jian He, Yudong Qiu, Xiaodong Han declare that they have no conflict of interest.

Supplementary material

10620_2019_5806_MOESM1_ESM.docx (1.3 mb)
Supplementary material 1 (DOCX 1296 kb)


  1. 1.
    Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 2013;119:3929–3942.CrossRefGoogle Scholar
  2. 2.
    Sirica AE, Gores GJ, Groopman JD, et al. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2018;69(4):1803–1815.CrossRefGoogle Scholar
  3. 3.
    Zhang CH, Xu H, Zhou ZP, et al. Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. Exp Ther Med. 2018;15:4995–5000.Google Scholar
  4. 4.
    Patel T. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol. 2014;49:165–172.CrossRefGoogle Scholar
  5. 5.
    Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003;10:265–281.CrossRefGoogle Scholar
  6. 6.
    Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607.CrossRefGoogle Scholar
  7. 7.
    Cookson MR. LRRK2 pathways leading to neurodegeneration. Curr Neurol Neurosci. 2015;15:42.CrossRefGoogle Scholar
  8. 8.
    Moehle MS, Webber PJ, Tse T, et al. LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci. 2012;32:1602–1611.CrossRefGoogle Scholar
  9. 9.
    Schapansky J, Nardozzi JD, LaVoie MJ. The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson’s disease. Neuroscience. 2015;302:74–88.CrossRefGoogle Scholar
  10. 10.
    Inzelberg R, Cohen OS, Aharon-Peretz J, et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology. 2012;78:781–786.CrossRefGoogle Scholar
  11. 11.
    Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.CrossRefGoogle Scholar
  12. 12.
    Looyenga BD, Furge KA, Dykema KJ, et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci USA. 2011;108:1439–1444.CrossRefGoogle Scholar
  13. 13.
    Waro BJ, Aasly JO. Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson’s disease. Brain Behav. 2018;8:e00858.CrossRefGoogle Scholar
  14. 14.
    Sierra M, Martinez-Rodriguez I, Sanchez-Juan P, et al. Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease. Neurology. 2017;89:439–444.CrossRefGoogle Scholar
  15. 15.
    Vilas D, Ispierto L, Alvarez R, et al. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. Parkinsonism Relat Disord. 2015;21:1170–1176.CrossRefGoogle Scholar
  16. 16.
    Park HJ, Jang KM, Kang TW, et al. Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on Gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol. 2016;26:3102–3111.CrossRefGoogle Scholar
  17. 17.
    Tsunematsu S, Chuma M, Kamiyama T, et al. Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. Abdom Imaging. 2015;40:1492–1499.CrossRefGoogle Scholar
  18. 18.
    Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT—correlation with clinicopathological findings. Eur Radiol. 2017;27:498–506.CrossRefGoogle Scholar
  19. 19.
    Wang C, Dai J, Sun Z, et al. Targeted inhibition of disheveled PDZ domain via NSC668036 depresses fibrotic process. Exp Cell Res. 2015;331:115–122.CrossRefGoogle Scholar
  20. 20.
    Zhu Y, Chen J, Kong WW, et al. Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features. Eur Radiol. 2018;28:159–169.CrossRefGoogle Scholar
  21. 21.
    Shuang Z, Mao Y, Lin G, et al. Alpha-L-fucosidase serves as a prognostic indicator for intrahepatic cholangiocarcinoma and inhibits its invasion capacity. Biomed Res Int. 2018;2018:8182575.CrossRefGoogle Scholar
  22. 22.
    Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:44–54.CrossRefGoogle Scholar
  23. 23.
    Thanee M, Loilome W, Techasen A, et al. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis. Asian Pac J Cancer Prev. 2015;16:3043–3050.CrossRefGoogle Scholar
  24. 24.
    Gardet A, Benita Y, Li C, et al. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol. 2010;185:5577–5585.CrossRefGoogle Scholar
  25. 25.
    Pons B, Armengol G, Livingstone M, et al. Association between LRRK2 and 4E-BP1 protein levels in normal and malignant cells. Oncol Rep. 2012;27:225–231.Google Scholar
  26. 26.
    Chan SL, Tan EK. Targeting LRRK2 in Parkinson’s disease: an update on recent developments. Expert Opin Ther Targets. 2017;21:601–610.CrossRefGoogle Scholar
  27. 27.
    Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015;58:419–432.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower HospitalThe Affiliated Hospital of Nanjing University Medical SchoolNanjingChina
  2. 2.Department of Pathology, Nanjing Drum Tower HospitalThe Affiliated Hospital of Nanjing University Medical SchoolNanjingChina
  3. 3.Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical SchoolNanjing UniversityNanjingChina
  4. 4.Jiangsu Key Laboratory of Molecular MedicineNanjing UniversityNanjingChina
  5. 5.Department of Radiology, Nanjing Drum Tower HospitalThe Affiliated Hospital of Nanjing University Medical SchoolNanjingChina

Personalised recommendations